Talk:Cystic fibrosis

message: "CF can result from more than a thousand different mutations, and as of 2006 it is not possible to test for each one. Testing analyzes the blood for the most common mutations such as ΔF508"
Presumably there has been some progress over the last ten years.
David Cary Hart (talk) 15:24, 19 June 2016 (UTC)
replies: text: Updated to 2016. Still appears to be true. Doc James (talk · contribs · email) 17:14, 19 June 2016 (UTC)
thread_title:  Requires an update 

message: doi:10.1016/S0140-6736(16)00576-6 JFW | T@lk 08:37, 2 September 2016 (UTC)
thread_title:  Lancet seminar 

message: doi:10.1016/S0140-6736(16)00576-6 JFW | T@lk 22:55, 19 November 2016 (UTC)
replies: text: Hahaha, the section above was created when this article was "online first". It's now in print. JFW | T@lk 22:56, 19 November 2016 (UTC)
thread_title:  Lancet seminar 

message: Shouldn't we mention furanones ?FuranonesBiofilm-inhibiting chemical protects surfaces They can be used to treat cystic fibrosis (described by Michael Givskov of the Technical University of Denmark). See http://www.nature.com/news/2002/020111/full/news020107-12.html
KVDP (talk) 12:56, 5 December 2016 (UTC)
replies: text: Would need a review article. Doc James (talk · contribs · email) 12:31, 9 January 2017 (UTC)
thread_title: Treatments

message: It is problematic that the image at the top of the page is of clubbed fingers.  That is something that only some people with CF have.  It would make much more sense to have a picture of lungs at the top, since that is a feature of CF that is the most common.  Alternatively, an illustration of the genetic defect would work.  Could someone please move the picture of clubbed fingers lower on the page and put something more relevant at the top?
CanadianJane (talk) 16:08, 3 August 2018 (UTC)
replies: text: Not really problematic. It is a classic finding and present in about 80% of people with the condition. Doc James (talk · contribs · email) 12:56, 4 August 2018 (UTC)
thread_title:  Problematic picture at top of entry 

message: I have reincorporated a source that was initially deleted as primary. It is an editorial that accompanied the publication of a study. It was used for context. I moved the entire section to treatment and am using the editorial for the context not included in the Cochrane review. I hope this passes muster. BiologicalMe (talk) 14:48, 5 September 2018 (UTC)
thread_title:  Ursodeoxycholic acid 

message: This article https://www.bbc.co.uk/news/av/disability-42358852/the-choir-that-can-never-sing-together states that "Any physical contact [with others with CF] poses a serious cross infection risk" and should therefore be avoided. Is this generally accepted? Would this be useful info to add to this article, in the Management section section for example? FrankSier (talk) 22:48, 15 September 2018 (UTC)
thread_title:  "Any physical contact [with others with CF] poses a serious cross infection risk" 

message: Would someone with more knowledge than I please add a section on this new drug. It is getting lots of press including here: https://www.washingtonpost.com/health/2019/10/31/long-awaited-cystic-fibrosis-drug-could-turn-deadly-disease-into-manageable-condition/  — Preceding unsigned comment added by 128.125.185.134 (talk) 19:32, 31 October 2019 (UTC)
thread_title:  New drug Trikafta 

message: So, I've been retired for 8 years. In the meantime, I've spent 5 years working as a researcher in this field and this article is dangerously out of date. In that time I've also forgotten all of the policies that I used to be able to type out in my sleep. I'd appreciate any help as I try cleaning up and overhauling this article to reflect the (much more positive!) current state of CF knowledge and treatment.  Danger High voltage! 16:18, 25 September 2021 (UTC)
replies: text: Hi  i was just reading this talk page. Did you have any success? Are there some areas/sections that you want to list here and maybe we can try to gather some secondary sources and tackle anything else. JenOttawa (talk) 21:10, 8 May 2023 (UTC)
thread_title:  Statement of intent 

message: I am not suitably qualified to feel comfortable removing this but it is not clearly based on fact.
'Comorbidities' and Intracellular electrolytes.
Persons with CF show an extraordinary number of "comorbidities" affecting almost every organ in the body. These have in the past been viewed as incidental and not caused directly by the faulty CFTR gene but that should be reconsidered. If Chloride is not being pumped out of cells because of the faulty CFTR channel, then the levels within the cells will be high and will need be balanced by increased cations (Potassium and Calcium in particular). High Calcium in the parathyroid cells may be expected to affect the function of that gland and so too the bones, causing hypoporosis. High intracellular potassium may be expected to affect Adrenal function causing hypokalaemia. Muscle activity may be affected by these electrolyte abnormalities including cardiomyopathy of the heart. Nerve function is affected by electrolytes esp. Potassium. The endocrine cells of the Pancreas that produce Insulin, in the Islets of Lanaghans, may be affected too. Our personal experience is that the response to treatment of Hypoglycemia is better if glucose is given in an electrolyte drink.
More research is needed into intracellular electrolytes in pwCF. We may well find the CFTR gene affects EVERY cell in the body not just those producing mucous. 118.93.131.49 (talk) 15:41, 31 May 2023 (UTC)
thread_title:  'Comorbidities' and Intracellular electrolytes section contains no references and seems quite anecdotal/opinionated